Photo from wikipedia
Key Points Question Can combined immune checkpoint inhibition improve overall survival (OS) in patients with advanced refractory colorectal cancer (CRC)? Findings In this randomized phase 2 study with 180 patients… Click to show full abstract
Key Points Question Can combined immune checkpoint inhibition improve overall survival (OS) in patients with advanced refractory colorectal cancer (CRC)? Findings In this randomized phase 2 study with 180 patients randomized in a 2:1 ratio to tremelimumab and durvalumab plus best supportive care or best supportive care alone, the median OS was 6.6 months for durvalumab and tremelimumab and 4.1 months for best supportive care; correlative analysis revealed that patients with plasma tumor mutation burden (TMB) of 28 or more variants per megabase had the greatest OS benefit. Meaning Combined immune checkpoint inhibition may prolong OS in patients with advanced refractory CRC.
Journal Title: JAMA Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!